Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Celgene, Agios Eye Cancer Metabolism
by Lisa M. Jarvis
April 26, 2010
| A version of this story appeared in
Volume 88, Issue 17
Celgene and Agios Pharmaceuticals have established a broad collaboration to discover and develop drugs targeting cancer metabolism. Celgene will pay $130 million in exchange for a stake in Agios and, for a period of time, exclusive rights to develop any drug candidates coming out of Agios’ pipeline. Agios is focused on depriving cancer cells of their energy source by using small molecules to control critical metabolic enzymes. Those targets include isocitrate dehydrogenase, shown to play a role in cancer formation, and pyruvate kinase M2, an enzyme involved in glucose metabolism.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter